Kiai Parsa purchased $9K of MED (indirect holdings)

Kiai Parsa purchased 661 indirectly-held shares of MEDIFAST INC (MED) at $13.03 on 2026-11-04.

Original reporting
SEC EDGAR · Kiai Parsa
Published Nov 6, 2026, 7:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MED
Neutral
high confidence
Mentioned
$MED
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDNeutralLow
01

Why it matters

The filing provides a fresh, primary source of insider activity but the transaction size is small, limiting market impact.

02

Market read

A modest insider buy that is unlikely to affect MED's price materially.

03

What to watch

Potential upcoming corporate actions or strategic moves not disclosed could make the purchase more meaningful.

Relevance 3/10Novelty 3/10Timing: post‑market on 2026‑11‑04

Background

SEC Form 4 filing discloses an insider purchase by a director of Medifast, Inc.

Company-level read

Ticker impact

$MEDNeutralHigh confidence
Context

Director Kiai Parsa bought 661 shares of MED at $13.03, increasing his holdings to 21,089 shares.

Expected impact

minor upward pressure as a small signal of confidence

Evidence & confidence

Form 4 filing shows a $8.6k purchase by a director; the amount is trivial relative to market cap, so any price effect will be limited.

Market effects

none

none

none

Counterpoint

The purchase may be routine portfolio rebalancing rather than a confidence signal.

Key entities

  • Medifast Inc.

    US‑listed health and nutrition company (ticker MED).

  • Kiai Parsa

    Director of Medifast who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDMed

5 insightful analyst questions from Medifast’s Q3 earnings call

Medifast's Q3 revenue exceeded expectations but declined year-over-year. Management cited the Trilogy brand's success and improved coach productivity. Analysts questioned coach engagement, competition with GLP-1 medications, and cost reduction. The stock is trading at $12.50. Key focus areas include Trilogy adoption, coach productivity, and cost efficiencies.

$MEDHigh

Why Medifast (MED) stock is trading up today

Medifast (MED) shares rose 6.2% after Q3 results beat expectations, with adjusted EBITDA of $1.9M. CEO Nick Johnson highlighted new product launches and guidance for Q4 revenue of $55M-$75M. Full-year revenue is expected at $280M-$300M, with a GAAP loss of $1.80-$2.05 per share.

$MEDMed

Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million

Medifast Inc (MED) reported Q3 2026 revenue of $72M, down 19.4% YoY, with revenue stabilizing near $75M for four quarters. CEO Nicholas Johnson highlighted high engagement and productivity among coaches, despite a decline in active coach numbers. The company expects continued productivity growth and cost efficiencies. Q4 revenue guidance is $55M-$75M, with EPS of $0-$0.25. Medifast has $172.5M in cash and no debt, with a target of profitability in Q4 2026.

$MEDMed

Medifast, Inc. Q3 2026 Earnings Call Summary

Medifast (MED) reported a 19.4% revenue decline in Q3 2026, attributing it to lower active coach counts due to GLP-1 medication adoption. The company is transitioning to a metabolic health system called Trilogy and implementing cost-cutting measures. Q4 2026 revenue is expected between $55M and $75M, with a focus on profitability and long-term growth. Management sees GLP-1s as a catalyst for consumer interest rather than a direct threat.

$MEDMed

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast (MED) reported a Q3 operating loss of $19.4M, including restructuring charges. The company introduced new products and highlighted GLP-1 medications' impact on client conversations. Medifast forecasts Q4 revenue of $55M-$75M and full-year 2026 revenue of $280M-$300M, aiming for profitability in Q4.